OBJECTIVE: The aim of this study was to test the proinflammatory action of human secreted phospholipase A2 (sPLA2) in an animal model of synovitis-like inflammation and to compare it with a Group 1 (porcine pancreatic) and a Group 2 (Naja mocambique mocambique) PLA2. METHODS: The subcutaneous injection of air in the rat pouch induced the formation of a connective tissue cavity lined with cells closely resembling a synovium. sPLA2 (0.01-10 micrograms/pouch) porcine pancreatic (10 micrograms/pouch), PLA2 or Naja mocambique mocambique PLA2 (10 micrograms/pouch) were injected in a 6-day rat air pouch. RESULTS: Our data show that recombinant human enzyme PLA2 (0.01-10 micrograms/pouch), but not Naja mocambique mocambique (Group 2 PLA2) and porcine pancreatic PLA2 (Group 1 PLA2), was able to exacerbate the inflammatory response without increasing eicosanoid release. CONCLUSION: Only sPLA2 was able to exacerbate rat air pouch and its effect was unrelated to eicosanoid release.
OBJECTIVE: The aim of this study was to test the proinflammatory action of humansecreted phospholipase A2 (sPLA2) in an animal model of synovitis-like inflammation and to compare it with a Group 1 (porcine pancreatic) and a Group 2 (Naja mocambique mocambique) PLA2. METHODS: The subcutaneous injection of air in the rat pouch induced the formation of a connective tissue cavity lined with cells closely resembling a synovium. sPLA2 (0.01-10 micrograms/pouch) porcine pancreatic (10 micrograms/pouch), PLA2 or Naja mocambique mocambique PLA2 (10 micrograms/pouch) were injected in a 6-day rat air pouch. RESULTS: Our data show that recombinant human enzyme PLA2 (0.01-10 micrograms/pouch), but not Naja mocambique mocambique (Group 2 PLA2) and porcine pancreaticPLA2 (Group 1 PLA2), was able to exacerbate the inflammatory response without increasing eicosanoid release. CONCLUSION: Only sPLA2 was able to exacerbate rat air pouch and its effect was unrelated to eicosanoid release.
Authors: C Jacques; G Béréziat; L Humbert; J L Olivier; M T Corvol; J Masliah; F Berenbaum Journal: J Clin Invest Date: 1997-04-15 Impact factor: 14.808
Authors: R Cholbi; M L Ferrándiz; M C Terencio; S De Rosa; M J Alcaraz; M Payá Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1996-11 Impact factor: 3.000
Authors: G J Wolbink; C Schalkwijk; J W Baars; J Wagstaff; H van den Bosch; C E Hack Journal: Cancer Immunol Immunother Date: 1995-11 Impact factor: 6.968